Jul 02, 2020
SciTech Development, LLC, a clinical stage specialty pharmaceutical company focused on novel, advanced drug delivery mechanisms for use with cancer therapeutics, is pleased to announced that it has received IRB Approval to enter the clinic at Rush...
Jun 10, 2020
SciTech Development announced that it will deliver a corporate presentation and meet with investors at the 2020 MedInvest Virtual Infectious Diseases and Immunology Conference, June 15-17, 2020.
Apr 16, 2020
NanoFenretinide may offer additional support in the battle against the COVID-19 pandemic
Mar 23, 2020
SciTech Development, LLC, a clinical stage biotechnology company focused on the development of cancer treatments, announced it has appointed Brian Leyland-Jones, MD, PhD as Chief Medical Officer (CMO). In this new role, Dr.
Mar 04, 2020
SciTech Development, a clinical stage drug development company, will deliver a corporate presentation and meet with investors at the NYC Spring Oncology Investor Conference 2020.
Dec 23, 2019
The U.S. Food and Drug Administration (FDA) has accepted SciTech Development's Investigational New Drug (IND) Application for ST-001 nanoFenretinide, an experimental treatment for T-cell non-Hodgkin's lymphoma (NHL).
Dec 07, 2019
SciTech Development announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in healthcare at the Hilton San Francisco Union Square.
Nov 22, 2019
SciTech Development is pleased to announce that it will be attending the J.P. Morgan Healthcare Conference January 12–16 in San Francisco, CA. SciTech will be participating in the BIO One-on-One Partnering™ @ JPM.
Oct 30, 2019
SciTech Development, a clinical stage drug development company, is pleased to announce that it has been invited to participate in the NYC Oncology Investor Conference 2019 at 1155 6th Ave 22nd Floor, New York, NY.
Oct 08, 2019
SciTech Development, a clinical stage drug development company, is pleased to announce that it will be presenting a poster at the 61st Annual American Society of Hematology (ASH) Meeting & Exposition in Orlando, Florida, December 7-10.